What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck?

Krengli, Marco; Jereczek‐Fossa, Barbara Alicja; Kaanders, Johannes H.A.M.; Masini, Laura; Beldì, Debora; Orecchia, Roberto

doi:10.1016/j.critrevonc.2007.07.001

Cited by 83 publications

(77 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whether R0 resected patients do benefit from additional radiotherapy is discussed controversially [3,4] and needs to be evaluated in a larger study population. Recent studies also showed that primary multilocular sinonasal melanoma does exist and forms a subtype that is associated with unfavorable local control independently of the postoperative procedure [5].…”

Section: Discussionmentioning

confidence: 99%

Noncutaneous Melanomas: A Single-Center Analysis

Prete¹,

Chaloupka²,

Holzmann³

et al. 2015

Dermatology

View full text Add to dashboard Cite

Background: The optimal treatment algorithm for noncutaneous melanomas must yet be established. Objective: To compare systemic treatment-relevant mutational status, metastatic pattern and response to systemic treatment in noncutaneous melanoma. Methods: Retrospective single-center study analyzing 64 noncutaneous melanoma patients treated between January 2006 and September 2013. Results: c-KIT mutations were found exclusively in vulvovaginal melanoma (4/7). Overall status for NRAS and BRAF mutations was low (1/7 and 0/21 detected mutations, respectively). Seven out of 7 vulvovaginal and 6/13 sinonasal melanomas first metastasized to lymph nodes, whereas 18/22 ocular melanomas first metastasized to the liver. Response to systemic treatment in vulvovaginal melanomas was best for imatinib with a disease control rate of 3/3 and overall for ipilimumab with a disease control rate of 3/10. Sorafenib was associated with adverse drug reactions (6/13) and poor results. Conclusion: Noncutaneous melanomas show few tumor-signaling pathway mutations and distinct metastasization patterns. Immunotherapy induces response rates in mucosal melanoma similar to those in cutaneous melanoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Noncutaneous Melanomas: A Single-Center Analysis

Prete¹,

Chaloupka²,

Holzmann³

et al. 2015

Dermatology

View full text Add to dashboard Cite

show abstract

“…This classification, missing T1 and T2 stages, can be attributed to the aggressive local growth pattern of this tumor entity with irregular borders, melanosis, and in-transit metastases [9]. conventional chemotherapies have not so far shown any significant benefit [10][11][12].…”

Section: Introductionmentioning

confidence: 98%

Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck

Thierauf¹,

Veit²,

Affolter

et al. 2015

Melanoma Research

View full text Add to dashboard Cite

Mucosal melanoma of the head and neck is a rare and aggressive tumor entity with a poor prognosis. The standard treatment is radical tumor resection, with or without adjuvant radiation, where conventional chemotherapies in advanced stage or recurrent diseases have shown little benefit. Overexpression of the programmed cell death ligand 1 (PD-L1) is a common feature in human cancer. Although PD-L1 is an acknowledged prognostic biomarker for dismal prognosis in other tumors of the head and neck, expression and clinical relevance of PD-L1 in mucosal melanoma have not been addressed so far. We assessed PD-L1 expression using immunohistochemical staining in 23 tumor samples from patients with primary mucosal melanoma and correlated expression status with clinicopathological and outcome data. Tumors were derived from the nasal cavity (43.5%), nasal sinuses (43.5%), and the conjunctiva (13%). All patients had undergone surgery; 39% of all patients received adjuvant radiation and 13% were administered systemic interferon therapy. The probability of 1- and 5-year overall survival was 87 and 34.8%, respectively. The mean overall survival was 51 months and the mean recurrence-free survival was 23 months. Immunohistochemical staining showed PD-L1 expression in 13% (3/23) of mucosal melanoma. In contrast, prominent PD-L1 staining was detected in 100% of tissue sections from a control group of cutaneous melanoma (n=9). PD-L1 expression in mucosal melanoma was not correlated with age, sex, nor anatomical localization of the tumor. Interestingly, patients with PD-L1-positive mucosal melanoma had a significantly longer recurrence-free survival (P=0.026). In contrast to cutaneous melanoma and some other malignancies, a relevant PD-L1 overexpression in mucosal melanoma could not be confirmed.

show abstract

“…In this study, no patient had locoregional failure as the only failure site, and no patient required salvage APR for the palliation of local-regional disease recurrence [4]. A number of studies in patients with mucosal melanoma of the head and neck also suggest better outcomes with postoperative radiotherapy; this approach is currently recommended for invasive melanoma in patients with positive or close excision margins [5].…”

Section: Discussionmentioning

confidence: 99%

Multimodality Treatment in the Management of Anorectal Melanoma: A Case Report and Review of the Literature

Tapan

Dizdar

Bulut

et al. 2011

EAJM

View full text Add to dashboard Cite

Anorectal melanoma represents approximately 0.2-1% of all malignant melanomas and has a poor prognosis, with a median survival of 8 to 23 months after the time of diagnosis. The typical treatment modalities include surgery, radiotherapy and chemotherapy. The particular approach taken depends on the patient's status and disease stage. Although there are different treatment options for this rare condition, there are not enough studies on multimodality treatment. Here, we present the case of a 54-year-old female with anorectal melanoma that had metastasized to an inguinal lymph node. She underwent local excision of the rectal mass and inguinal lymph-node dissection. Temozolomide treatment was started after radiotherapy and was given for 24 months. Follow-up revealed that the patient has been doing well with no signs of recurrence three years after the completion of treatment. We aim to discuss combined treatment modalities for ARM in light of the pertinent literature. Key Words: Anorectal melanoma, Multimodality treatment, Temozolomide ÖzetAnorektal melanoma; tüm malign melanoma vakalarının yaklaşık %0.2-1'ini oluşturmaktadır ve tanı anından itibaren 8-23 ay arasi ortalama yaşam süresiyle kötü bir prognoza sahiptir. Tedavi seçenekleri, hastanın performans skoru ve hastalık evresine gore cerrahi, radyoterapi ve kemoterapiden oluşmaktadır. Bu nadir durumun farkli tedavi seçenekleri olmasına rağmen multimodalite tedavi ile ilgili yeterli calışma bulunmamaktadır. Bu yazıda inguinal lenf nodu metastazı olan 54 yaşında bir bayan hasta sunulmuştur. Rektal kitlenin lokal eksizyonu ve inguinal lenf nodu diseksiyonunu takiben konvansiyonel radyoterapi uygulanan hastaya bu tedaviyi takiben 2 yıl süreyle temozolomide tedavisi verilmiştir. Tedavinin tamamlanmasından 3 yıl sonraki takiplerinde hastada henüz rekurrens bulgusuna rastlanmamıştır. Bu yazıda anorektal melanomanin multimodalite tedavisinin ilgili literatür ışığında tartışılması amaçlanmıştır.

show abstract

What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck?

Cited by 83 publications

References 41 publications

Noncutaneous Melanomas: A Single-Center Analysis

Noncutaneous Melanomas: A Single-Center Analysis

Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck

Multimodality Treatment in the Management of Anorectal Melanoma: A Case Report and Review of the Literature

Contact Info

Product

Resources

About